For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis Drugs is a kind of medicine for Osteoporosis, such as Fosamax, Actonel, Boniva, Zoledronic Acid (Reclast or Zometa) and others.
Scope of the Report:
Osteoporosis, which literally means porous bone, is a disease in which the density and quality of bone are reduced. As bones become more porous and fragile, the risk of fracture is greatly increased. The loss of bone occurs silently and progressively. Often there are no symptoms until the first fracture occurs. Osteoporosis drugs are a kind of medicine for Osteoporosis. The types of osteoporosis drugs mainly include antiresorptive drugs and anabolic drugs.
The Brazil osteoporosis drugs is Very concentrated, the sales of top eight manufacturers account exceeds 70% of Brazil sales.
The antiresorptive drugs is the main types of osteoporosis drugs. In 2015, the sales revenue of antiresorptive drugs is about 109 M USD; its proportion of total osteoporosis drugs exceeds 73%.
The worldwide market for Osteoporosis Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Osteoporosis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Eli Lilly
- Novartis
- Pfizer
- Amgen
- Merck
- Novo nordisk
- Actavis
- Roche
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Antiresorptive Drugs
- Anabolic Drugs
Market Segment by Applications, can be divided into
- Female
- Male
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Osteoporosis Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Osteoporosis Drugs, with price, sales, revenue and global market share of Osteoporosis Drugs in 2017 and 2018.
Chapter 3, the Osteoporosis Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Osteoporosis Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Osteoporosis Drugs market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Osteoporosis Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.